Menu
Back to Journals » Vascular Health and Risk Management » Volume 9
Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk
Received 2 May 2013
Accepted for publication 1 July 2013
Published 25 July 2013 Volume 2013:9 Pages 429—433
DOI https://doi.org/10.2147/VHRM.S34421
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Cong Zou,1 Honglin Hu2
1Department of Endocrinology, Fourth Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China; 2Department of Urology, Second Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China
Abstract: Pioglitazone and other thiazolidinediones (TZDs) initially showed great promise as unique receptor-mediated oral therapy for type 2 diabetes, but a host of serious side effects, primarily cardiovascular, have limited their utility. It is crucial at this point to perform a risk–benefit analysis to determine what role pioglitazone should play in our current treatment of type 2 diabetes and where the future of this class of drugs is headed. This review provides a comprehensive overview of the present literature. Clinical data currently available indicate that pioglitazone is an effective and generally well-tolerated treatment option for use in patients with type 2 diabetes. Pioglitazone can still reduce adverse cardiovascular risk.
Keywords: pioglitazone, diabetes, cardiovascular risk
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.